Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016 | Original Article

Esculin and its oligomer fractions inhibit adhesion and migration of U87 glioblastoma cells and in vitro angiogenesis

Authors: Imen Mokdad-Bzeouich, Hervé Kovacic, Kamel Ghedira, Latifa Chebil, Mohamed Ghoul, Leila Chekir-Ghedira, José Luis

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

Cancer metastasis is the major cause of cancer-related death. Chemoprevention is defined as the use of natural or synthetic substances to prevent cancer formation or cancer progress. In the present study, we investigate the antitumor activity of esculin and its oligomer fractions in U87 glioblastoma cells. We showed that esculin and its oligomers reduced U87 cell growth in a dose dependent manner. They also inhibited cell adhesion to collagen IV and vitronectin by interfering with the function of their respective receptors α2β1 and αvβ5 integrins. Furthermore, the tested samples were able to reduce migration of U87 cells towards another extracellular matrix fibronectin. Moreover, esculin and its oligomer fractions inhibited in vitro angiogenesis of endothelial cells (HMEC-1). In summary, our data provide the first evidence that esculin and its oligomer fractions are able to reduce adhesion, migration of glioblastoma cells and in vitro angiogenesis. Esculin and its oligomers may thus exert multi-target functions against cancer cells.
Literature
1.
Abdullaev IF, Rudkouskaya A, Mongin AA, Kuo YH. Calcium-activated potassium channels BK and IK1 are functionally expressed in human gliomas but do not regulate cell proliferation. PLoS One. 2010;5:12304.CrossRef
2.
Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol. 2008;31:300–5.CrossRefPubMed
3.
Zhang X, Zhang W, Cao WD, Cheng G, Zhang YQ. Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). Exp Ther Med. 2012;3:9–14.PubMed
4.
Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113:1953–68.CrossRefPubMedPubMedCentral
5.
Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62:753–64.CrossRefPubMed
6.
7.
8.
Ong EB, Watanabe N, Saito A, Futamura Y, Abd El Galil KH, Koito A, et al. Vipirinin, a coumarin-based HIV-1 Vpr inhibitor, interacts with a hydrophobic region of VPR. J Biol Chem. 2011;286:14049–56.
9.
Golfakhrabadi F, Abdollahi M, Ardakani MR, Saeidnia S, Akbarzadeh T, Ahmadabadi AN, et al. Anticoagulant activity of isolated coumarins (suberosin and suberenol)and toxicity evaluation of Ferulagocarduchorum in rats. Pharm Biol. 2014;52:1335–40.
10.
Canning C, Sun S, Ji X, Gupta S, Zhou K. Antibacterial and cytotoxic activity of isoprenylated coumarin mammea A/AA isolated from Mammea africana. J Ethnopharmacol. 2013;147:259–62.CrossRefPubMed
11.
Sashidhara KV, Rosaiah JN, Kumar A, Bhatia G, Khanna AK. Synthesis of novel benzocoumarin derivatives as lipid lowering agents. Bioorg Med Chem Lett. 2010;20:3065–9.CrossRefPubMed
12.
Nasr T, Bondock S, Youns M. Anticancer activity of new coumarin substituted hydrazide-hydrazone derivatives. Eur J Med Chem. 2014;76:539–48.CrossRefPubMed
13.
Neelgundmath M, Dinesh KR, Mohan CD, Li F, Dai X, Siveen KS, et al. Novel synthetic coumarins that targets NF-κB in Hepatocellular carcinoma. Bioorg Med Chem Lett. 2015;25:893–7.
14.
Stefanova TH, Nikolova NJ, Toshkova RA, Neychev HO. Antitumor and immunomodulatory effect of coumarin and 7-hydroxycoumarin against Sarcoma 180 in mice. J Exp Ther Oncol. 2007;6:107–15.PubMed
15.
Zhao DL, Zou LB, Lin S, Shi JG, Zhu HB. Anti-apoptotic effect of esculin on dopamine-induced cytotoxicityin the human neuroblastoma SH-SY5Y cell line. Neuropharmacology. 2007;53:724–32.CrossRefPubMed
16.
Rios ER, Rocha NF, Venâncio ET, Moura BA, Feitosa ML, Cerqueira GS, et al. Mechanisms involved in the gastroprotective activity of esculin on acute gastric lesions in mice. Chem Biol Interact. 2010;188:246–54.
17.
Ben Rhouma G, Chebil L, Krifa M, Ghoul M, Chekir-Ghedira L. Evaluation of mutagenic and antimutagenic activities of oligorutin and oligoesculin. Food Chem. 2012;135:1700–7.CrossRefPubMed
18.
Witaicenis A, Seito LN, da Silveira CA, de Almeida LD, Jr LAC, Rodrigues-Orsi P, et al. Antioxidant and intestinal anti inflammatory effects of plant-derived coumarin derivatives. Phytomedicine. 2014;21:240–6.
19.
Rahman MM. Evaluation of Hymenodictyon excelsum Phytochemical’s Therapeutic value against Prostate Cancer by Molecular Docking Study. Jundishapur J Nat Pharm Prod. 2015;10, e18216.CrossRefPubMedPubMedCentral
20.
Pourroy B, Honoré S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C, et al. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res. 2006;66:3256–63.
21.
Rigot V, Lehmann M, Andre’ F, Daemi N, Marvaldi J, Luis J. Integrin ligation and PKC activation are required for migration of colon carcinoma cells. J Cell Sci. 1998;111:3119–27.PubMed
22.
Kadi A, Pichard V, Lehmann M, Briand C, Braguer D, Marvaldi J, et al. Effect of microtubule disruption on cell adhesion and spreading. Biochem Biophys Res Comm. 1998;246:690–5.
23.
Morjen M, Kallech-Ziri O, Bazaa A, Othman H, Mabrouk K, Zouari-Kessentini R, et al. PIVL, a new serine protease inhibitor from Macrovipera lebetina transmediterranea venom, impairs motility of human glioblastoma cells. Matrix Biol. 2013;32:52–62.
24.
Pilorget A, Conesa M, Sarray S, Michaud-Levesque J, Daoud S, Kim KS, et al. Lebectin, a Macrovipera lebetina venom-derived C-type lectin, inhibits angiogenesis both in vitro and in vivo. J Cell Physiol. 2007;211:307–15.
25.
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310:1842–50.CrossRefPubMed
26.
Mohler JL, Gomella LG, Crawford ED, Glode LM, Zippe CD, Fair WR, et al. Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma. Prostate. 1992;20:123–31.
27.
Thornes RD, Daly L, Lynch G, Breslin B, Browne H, Browne HY, et al. Treatment with coumarin to prevent or delay recurrence of malignant melanoma. J Cancer Res Clin Oncol. 1994;120:32–4.CrossRef
28.
Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25:234–40.CrossRefPubMedPubMedCentral
29.
Velasco-Velázquez MA, Agramonte-Hevia J, Barrera D, Jiménez-Orozco A, García-Mondragón MJ, Mendoza-Patiño N, et al. 4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts, decreasing their adhesion to extracellular matrix proteins and motility. Cancer Lett. 2003;198:179–86.
30.
Delamarre E, Taboubi S, Mathieu S, Bérenguer C, Rigot V, Lissitzky JC, et al. Expression of integrin alpha 6 beta1 enhances tumorigenesis in glioma cells. Am J Pathol. 2009;175:844–55.
31.
32.
Kielbus M, Skalicka-Wozniak K, Grabarska A, Jeleniewicz W, Dmoszynska-Graniczka M, Marston A, et al. 7-substituted coumarins inhibit proliferation and migration of laryngeal cancer cells in vitro. Anticancer Res. 2013;33:4347–56.
33.
Lü HQ, Niggemann B, Zänker KS. Suppression of the proliferation and migration of oncogenic ras-dependent cell lines, cultured in a three-dimensional collagen matrix, by flavonoid-structured molecules. J Cancer Res Clin Oncol. 1996;122:335–42.CrossRefPubMed
34.
Sottile J. Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta. 2004;1654:13–22.PubMed
35.
Cheng TM, Murad YM, Chang CC, Yang MC, Baral TN, Cowan A, et al. Single domain antibody against carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits proliferation, migration, invasion and angiogenesis of pancreatic cancer cells. Eur J Cancer. 2014;50:713–21.
36.
Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001;154:1069–79.
37.
Thyboll J, Kortesmaa J, Cao R, Soininen R, Wang L, Iivanainen A, et al. Deletion of the laminin a4 chain leads to impaired microvessel maturation. Mol Cell Biol. 2002;22:1194–202.
38.
Nam NH, Kim Y, You YJ, Hong DH, Kim HM, Ahn BZ. Preliminary structure antiangiogenic activity relationships of 4-senecioyloxymethyl-6,7-dimethoxycoumarin. Bioorg Med Chem Lett. 2002;12:2345–8.CrossRefPubMed
39.
Lee S, Sivakumar K, Shin WS, Xie F, Wang Q. Synthesis and anti-angiogenesis activity of coumarin derivatives. Bioorg Med Chem Lett. 2006;16:4596–9.CrossRefPubMed
40.
Vijay Avin BR, Thirusangu P, Lakshmi Ranganatha V, Firdouse A, Prabhakar BT, Khanum SA. Synthesis and tumor inhibitory activity of novel coumarin analogs targeting angiogenesis and apoptosis. Eur J Med Chem. 2014;75:211–21.
41.
Tucher GC. Integrins: molecular targets in cancer therapy. Curr oncol Rep. 2006;8:96–103.CrossRef
42.
Mokdad-Bzeouich I, Mustapha N, Chaabane F, Ghedira Z, Ghedira K, Ghoul M, et al. Oligomerization of esculin improves its antibacterial activity and modulates antibiotic resistance. J Antibiot (Tokyo). 2015;68:148–5.
Metadata
Title
Esculin and its oligomer fractions inhibit adhesion and migration of U87 glioblastoma cells and in vitro angiogenesis
Authors
Imen Mokdad-Bzeouich
Hervé Kovacic
Kamel Ghedira
Latifa Chebil
Mohamed Ghoul
Leila Chekir-Ghedira
José Luis
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4209-1

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Original Article

The influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study

Original Article

miR-218 suppressed the growth of lung carcinoma by reducing MEF2D expression

Original Article

Icaritin activates JNK-dependent mPTP necrosis pathway in colorectal cancer cells

Original Article

IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients

Review

Extracellular vesicles in breast cancer drug resistance and their clinical application

Original Article

The role of MALAT1/miR-1/slug axis on radioresistance in nasopharyngeal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits